Subtopic Deep Dive
Systemic Therapy for Metastatic Angiosarcoma
Research Guide
What is Systemic Therapy for Metastatic Angiosarcoma?
Systemic therapy for metastatic angiosarcoma uses taxanes, anti-angiogenics, and anthracyclines to treat advanced vascular sarcomas with poor prognosis.
Clinical trials like ANGIOTAX demonstrate weekly paclitaxel efficacy in unresectable angiosarcoma (Penel et al., 2008, 680 citations). NCCN guidelines recommend taxanes and pazopanib for advanced soft tissue sarcomas including angiosarcoma (von Mehren et al., 2022, 1099 citations; von Mehren et al., 2018, 720 citations). Sorafenib shows activity in metastatic sarcomas (Maki et al., 2009, 569 citations). Over 20 key papers guide subtype-specific progression-free survival outcomes.
Why It Matters
Metastatic angiosarcoma has median survival under 1 year, creating urgent need for effective systemic options in this orphan disease (Penel et al., 2008). Weekly paclitaxel achieves 62% response rate in ANGIOTAX trial, informing first-line use for cutaneous subtypes (Penel et al., 2008). NCCN guidelines integrate these data for taxane preference over doxorubicin in vascular sarcomas (von Mehren et al., 2022). Pazopanib and sorafenib target angiogenesis, extending PFS in phase II trials (Maki et al., 2009; von Mehren et al., 2018). These therapies address unmet needs in radiation-associated and visceral angiosarcomas.
Key Research Challenges
Subtype-Specific Efficacy Variation
Angiosarcoma subtypes (cutaneous vs. visceral) respond differently to taxanes and anti-angiogenics (Penel et al., 2008). ANGIOTAX showed higher responses in scalp/face lesions versus deep tumors. Lack of randomized data hinders optimal regimen selection (von Mehren et al., 2022).
Limited Phase III Evidence
Most data from phase II trials like ANGIOTAX and sorafenib studies, with small cohorts under 50 patients (Penel et al., 2008; Maki et al., 2009). Doxorubicin-ifosfamide intensification fails superiority in advanced sarcomas (Judson et al., 2014). Progression-free survival endpoints vary by prior therapy.
Toxicity in Elderly Patients
Angiosarcoma predominates in elderly (median age 70+), where weekly paclitaxel causes neuropathy (Penel et al., 2008). Sorafenib induces hand-foot syndrome in 50% (Maki et al., 2009). Guidelines stress dose adjustments per NCCN (von Mehren et al., 2022).
Essential Papers
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson, Jaap Verweij, Hans Gelderblom et al. · 2014 · The Lancet Oncology · 1.1K citations
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, John M. Kane, Mark Agulnik et al. · 2022 · Journal of the National Comprehensive Cancer Network · 1.1K citations
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blo...
A clinical and pathological staging system for soft tissue sarcomas
William O. Russell, Jonathan Cohen, Franz M. Enzinger et al. · 1977 · Cancer · 765 citations
Introduction<br/>The theory of magnetohydrodynamics (MHD) is valuable because it leads to baseline considerations for toroidal magnetic configurations, even when the parameter ranges in which...
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, R. Lor Randall, Robert S. Benjamin et al. · 2018 · Journal of the National Comprehensive Cancer Network · 720 citations
Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blo...
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
Nicolas Penel, Binh Bui, Jacques‐Olivier Bay et al. · 2008 · Journal of Clinical Oncology · 680 citations
Purpose The objective of this phase II trial was to assess the efficacy and toxicity of weekly paclitaxel for patients with metastatic or unresectable angiosarcoma. Patients and Methods Thirty pati...
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
Robert G. Maki, David R. D’Adamo, Mary Louise Keohan et al. · 2009 · Journal of Clinical Oncology · 569 citations
Purpose Since activity of sorafenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study of daily oral sorafenib in patients with recurrent or metastatic s...
Angiosarcoma of the face and scalp, prognosis and treatment
Colin A. Holden, Margaret F Spittle, Edward Wilson Jones · 1987 · Cancer · 542 citations
72 patients with angiosarcoma (AS) of the face and scalp have been analyzed with respect of various prognostic factors and the effects of different treatment regimes. This disease predominantly occ...
Reading Guide
Foundational Papers
Start with ANGIOTAX (Penel et al., 2008, 680 citations) for paclitaxel benchmark in unresectable angiosarcoma; Judson et al. (2014, 1119 citations) for doxorubicin standards in metastatic sarcomas; Maki et al. (2009, 569 citations) for sorafenib in recurrent cases.
Recent Advances
NCCN 2022 (von Mehren et al., 1099 citations) updates taxane/anti-angiogenic roles; UK guidelines (Dangoor et al., 2016, 475 citations) refine sarcoma management including angiosarcoma.
Core Methods
Weekly paclitaxel dosing (80 mg/m²; Penel et al., 2008); sorafenib 400 mg BID (Maki et al., 2009); PFS as primary endpoint per RECIST; subtype stratification (cutaneous/visceral) in NCCN (von Mehren et al., 2022).
How PapersFlow Helps You Research Systemic Therapy for Metastatic Angiosarcoma
Discover & Search
Research Agent uses searchPapers('systemic therapy metastatic angiosarcoma taxane') to find ANGIOTAX (Penel et al., 2008), then citationGraph reveals 680 citing papers on taxane outcomes. exaSearch uncovers NCCN updates (von Mehren et al., 2022), while findSimilarPapers links sorafenib data (Maki et al., 2009) to pazopanib trials.
Analyze & Verify
Analysis Agent applies readPaperContent on ANGIOTAX to extract 62% response rates, then runPythonAnalysis plots PFS Kaplan-Meier curves from trial data using pandas/matplotlib. verifyResponse with CoVe cross-checks claims against Judson et al. (2014), achieving GRADE B evidence for taxanes in vascular subtypes. Statistical verification confirms sorafenib PFS hazard ratios (Maki et al., 2009).
Synthesize & Write
Synthesis Agent detects gaps in visceral angiosarcoma data versus cutaneous, flagging contradictions between sorafenib and paclitaxel efficacy (Maki et al., 2009; Penel et al., 2008). Writing Agent uses latexEditText for regimen tables, latexSyncCitations for 20+ references, and latexCompile for trial comparison PDFs. exportMermaid generates PFS flowchart diagrams.
Use Cases
"Extract survival data from ANGIOTAX and run statistical analysis on PFS by subtype"
Research Agent → searchPapers('ANGIOTAX Penel') → Analysis Agent → readPaperContent + runPythonAnalysis (pandas survival curves, log-rank test) → matplotlib PFS plot with p-values
"Draft NCCN-compliant treatment algorithm for metastatic angiosarcoma in LaTeX"
Synthesis Agent → gap detection (von Mehren 2022 vs Penel 2008) → Writing Agent → latexEditText (algorithm) → latexSyncCitations (NCCN/Judson) → latexCompile → PDF with taxane flowchart
"Find code for angiosarcoma genomic analysis from related sarcoma papers"
Research Agent → searchPapers('sarcoma angiosarcoma genomics') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → R survival package for PFS modeling
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'metastatic angiosarcoma systemic therapy', chains citationGraph to ANGIOTAX influencers, and outputs structured review with GRADE scores. DeepScan applies 7-step CoVe to verify taxane superiority (Penel et al., 2008 vs Judson et al., 2014), checkpointing PFS stats. Theorizer generates hypotheses on anti-angiogenic combos from sorafenib/NCCN data (Maki et al., 2009; von Mehren et al., 2022).
Frequently Asked Questions
What defines systemic therapy for metastatic angiosarcoma?
Systemic therapy includes weekly paclitaxel (62% response in ANGIOTAX; Penel et al., 2008), sorafenib (Maki et al., 2009), and NCCN-recommended taxanes/pazopanib for advanced vascular sarcomas (von Mehren et al., 2022).
What are key methods in trials?
Phase II designs assess response rates and PFS, like ANGIOTAX weekly paclitaxel (Penel et al., 2008) and multi-arm sorafenib for sarcomas (Maki et al., 2009). Doxorubicin-ifosfamide randomization tests intensification (Judson et al., 2014).
What are key papers?
ANGIOTAX (Penel et al., 2008, 680 citations) proves paclitaxel efficacy; NCCN 2022 (von Mehren et al., 1099 citations) guides practice; sorafenib phase II (Maki et al., 2009, 569 citations) targets angiogenesis.
What open problems remain?
Randomized phase III trials lacking for angiosarcoma subtypes; optimal sequencing of taxanes vs. anti-angiogenics unclear (von Mehren et al., 2022); elderly toxicity management needs data beyond phase II (Penel et al., 2008).
Research Vascular Tumors and Angiosarcomas with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Systemic Therapy for Metastatic Angiosarcoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Vascular Tumors and Angiosarcomas Research Guide